

---

**Product Data Sheet**

---

Product Name: Prazosin  
Cat. No.: GC16785

**Chemical Properties**

Cas. No. 19216-56-9

Chemical Name [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(furan-2-yl)methanone

SMILES COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC

Formula  $C_{19}H_{21}N_5O_4$  M.Wt 383.4

Solubility DMSO : 41.67 mg/mL (108.69 mM; ultrasonic and warming and heat to 60°C); H<sub>2</sub>O : < 0.1 mg/mL (insoluble) Store Storage at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

**Protocol****Cell experiment****[1]:**

Cell lines MG63 and 143B cells

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

**Product Data Sheet**

---

Preparation Method	Cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) medium supplemented with 10% fetal bovine serum (FBS) at 37 °C with 5% CO <sub>2</sub> . The cells were treated with different concentrations of Prazosin (0, 2.5, 5, 7.5, 10, 15, 20, 30, 40, and 50μM), with Prazosin's effect on cell viability being analyzed by CCK8 assay. After treatment for 24h, cells were cultured with CCK8 reagent (10μL/well) at 37°C for 90min with absorbance being measured at 450nm.
Reaction Conditions	0, 2.5, 5, 7.5, 10, 15, 20, 30, 40, and 50μM; 24h
Applications	Prazosin dose-dependently reduced the viability of MG63 and 143B cells.

**Animal experiment [2]:**

Animal models C57 Bl/6 J mice

Preparation Method Each mouse was tested only once. The group n was 9 to 10. The basal tail-flick scores were first measured followed by a second tail-flick measurement 30min after i.p. administration of the test drugs (Prazosin 0.01, 0.1, 0.25, 0.5, 1 or 2mg/kg, or clonidine 5mg/kg, or cirazoline 0.3mg/kg, or corynanthine 0.5mg/kg, or saline). Then, a 5mg/kg test dose of morphine was administered to all mice, and 30min later, tail-flick scores were measured for the third time. Tail-flick scores were converted to %MPE (Maximal Possible Effect):  
$$\%MPE = \frac{\text{measured tail-flick score} - \text{average tail-flick score of saline-treated control group}}{\text{cutoff time} - \text{average tail-flick score of saline-treated control group}} \times 100\%$$

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

**Product Data Sheet**

---

Dosage form            0.01, 0.1, 0.25, 0.5, 1 and 2mg/kg/day; single-dose; i.p.

Applications            Prazosin enhances the analgesic effect of morphine in the tail flick test in mice, while Prazosin given alone has no analgesic effect.

**References:**

[1] An M, Ma W H,  
Jia H W, et al.

Prazosin inhibits  
the growth and  
mobility of  
osteosarcoma  
cells[J].

Translational  
cancer research,  
2019, 8(5): 1997.

[2] Özdoğan Ü K,  
Lähdesmäki J,  
Scheinin M.

Influence of  
prazosin and  
clonidine on  
morphine  
analgesia,  
tolerance and  
withdrawal in  
mice[J]. European  
journal of  
pharmacology,  
2003, 460(2-3):  
127-134.

**Background**

**Caution: Product has not been fully validated for medical applications. For research use only.**

**Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com**

**Address: 10292 Central Ave. #205, Montclair, CA, USA**

---

## Product Data Sheet

---

### Background

Prazosin is a specific antagonist of the  $\alpha_1$ -adrenergic receptor ( $\alpha_1$ -AR), with binding constants ( $K_i$  values) of 0.2, 0.25, and 0.32nM for human recombinant  $\alpha_1$ A-AR,  $\alpha_1$ B-AR, and  $\alpha_1$ D-AR, respectively, and 340 and 3.7nM for  $\alpha_2$ -AR (in HT-29 cells expressing  $\alpha_2$ A-AR and NG108 cells expressing  $\alpha_2$ B-AR) [1-2]. The  $\alpha_1$ -AR belongs to the seven-transmembrane structure and G protein-coupled receptor superfamily, and  $\alpha_1$ -AR located in the central and peripheral nervous systems have significant therapeutic significance [3]. Prazosin can have anti-inflammatory effects, relieve anxiety, alleviate panic, prevent memory decline, and regulate the analgesic effect of opioid drugs, and can be used in the research of hypertension and Alzheimer's disease [4].

In vitro, Prazosin (0, 2.5, 5, 7.5, 10, 15, 20, 30, 40, and 50 $\mu$ M; 24h) dose-dependently reduced the viability of MG63 and 143B cells and significantly weakened the cell migration and invasion ability. Prazosin inhibits the Akt/mTOR pathway by down-regulating the phosphorylation levels of Akt and mTOR and the expression of P70 and cyclin D1 [5]. Prazosin (30 $\mu$ M; 1h) pretreatment significantly increased the cytotoxicity of docetaxel-induced PC-3 and -LNCaP cells [6].

In vivo, Prazosin (1mg/kg/day; 2 weeks; i.p.) treatment can prevent memory decline in Alzheimer's disease (AD) mice, increase the anti-inflammatory response and astrocyte activation of mice, and significantly increase the number of GFAP-positive cells and neuronal cells [1]. Prazosin (0.01, 0.1, 0.25, 0.5, 1, and 2mg/kg/day; single-dose; i.p.) enhances the analgesic effect of morphine in mice in the tail flick test, while Prazosin alone has no analgesic effect [7].

### References:

- [1] Katsouri L, Vizcaychipi MP, McArthur S, et al. Prazosin, an  $\alpha(1)$ -adrenoceptor antagonist, prevents memory deterioration in the APP23 transgenic mouse model of Alzheimer's disease. *Neurobiol Aging*. 2013;34(4):1105-1115.
- [2] Bylund DB, Ray-Prenger C. Alpha-2A and alpha-2B adrenergic receptor subtypes: attenuation of cyclic AMP production in cell lines containing only one receptor subtype. *J Pharmacol Exp Ther*. 1989;251(2):640-644.
- [3] Sarma P K S, Tiwari A, Pal A.  $\alpha_1$ -Adrenoceptors as potential therapeutic targets[J]. *Expert Opinion on Therapeutic Patents*, 2005, 15(10): 1333-1351.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

## Product Data Sheet

---

- [4] Ozdoğan UK, Lähdesmäki J, Scheinin M. Influence of prazosin and clonidine on morphine analgesia, tolerance and withdrawal in mice. *Eur J Pharmacol.* 2003;460(2-3):127-134.
- [5] An M, Ma W H, Jia H W, et al. Prazosin inhibits the growth and mobility of osteosarcoma cells[J]. *Translational cancer research*, 2019, 8(5): 1997.
- [6] Spencer B H, McDermott C M, Chess-Williams R, et al. Prazosin but not tamsulosin sensitises PC-3 and LNCaP prostate cancer cells to docetaxel[J]. *Pharmacology*, 2018, 102(1-2): 17-25.
- [7] Ozdoğan UK, Lähdesmäki J, Scheinin M. Influence of prazosin and clonidine on morphine analgesia, tolerance and withdrawal in mice. *Eur J Pharmacol.* 2003;460(2-3):127-134.

**Caution: Product has not been fully validated for medical applications. For research use only.**

**Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com**

**Address: 10292 Central Ave. #205, Montclair, CA, USA**